Summary
The relative efficacy of two twice-daily insulin regimens using highly purified insulins, once daily Ultratard with twice daily Actrapid (ultralente/soluble) and twice daily Actrapid with twice daily Retard (soluble/isophane), has been studied in 12 diabetics in a cross-over study. Control was optimised as an out-patient, and assessed by in-patient 24 hour profiles. Similar day-time glucose control was achieved, but the mean overnight plasma glucose concentrations were more steady on ultralente/soluble (0100, 0300, 0500, 0700, 0800 h values 5.6, 5.3, 5.8, 7.8, 10.4 mmol/l) than on soluble/isophane (4.3, 3.4, 5.2, 7.5, 12.2 mmol/l). The minimum overnight plasma glucose concentrations were lower (p < 0.05) on soluble/isophane (mean 2.8 mmol/l) than on ultralente/soluble (mean 4.8 mmol/l), associated with higher (p < 0.05) nocturnal free plasma insulin levels after the evening soluble/isophane injection. The plasma glucose rise between 0700 and 0800 h was greater (p < 0.05) on soluble/isophane than on ultralente/soluble. The morning insulin injection should probably be taken immediately on rising, to prevent the pre-breakfast plasma glucose rise. The ultralente/ soluble combination gave similar day-time plasma glucose control to soluble/isophane with less nocturnal hypoglycaemia.
Article PDF
Similar content being viewed by others
References
Tchobroutsky G (1976) Relation of diabetic control to development of microvascular complications. Diabetologia 15: 143–152
Gokal R Harding P, Turner RC (1977) Comparison between the plasma insulin and glucose responses to five different insulin regimes in diabetic patients. Clin Endocrinol 7:301–305
Werther GA, Jenkins PA, Turner RC, Baum JD (1980) Twenty four hour metabolic profiles in diabetic children receiving insulin injections once or twice daily. Br Med J 1:414–418
Clarke BF, Munro JF, Duncan LJP (1965) Time-action studies and clinical trial of Actrapid and Crystal II Novo insulins. Br Med J 2:265–267
Oakley W, Hill D, Oakley NW (1966) Combined use of regular and crystalline protamine (NPH) insulins in the treatment of severe diabetes. Diabetes 15:219–221
Sönksen PH, Judd SL, Lowy C (1978) Home monitoring of blood glucose. Lancet 1:729–732
Slama G, Garrel DG, Tchobroutsky G (1980) Multiple daily injections through subcutaneously implanted needle. Lancet 1:1078
Phillips M, Simpson RW, Holman RR, Turner RC (1979) A simple and rational twice-daily insulin regime. Q J Med 191: 493–506
Turner RC, Holman RR (1978) Automatic lancet for capillary blood sampling. Lancet 2:713
Howe-Davies S, Holman RR, Phillips M, Turner RC (1978) Home blood sampling for plasma glucose assay in control of diabetes. Br Med J 2:596–598
Holman RR, Turner RC (1977) Diabetes: The quest for basal normoglycaemia. Lancet 1:469–474
Kuzuya H, Blix PM, Horwitz DH, Steiner DF, Rubenstein AH (1977) Determination of free and total insulin and C-peptide in insulin-treated diabetes. Diabetes 26:22–29
Beardwell CG, Burke CW, Cope CL (1968) Urinary free cortisol measured by competitive protein binding. Endocrinology 42:79–89
Gale EAM, Kurtz AB, Tattersall RB (1980) In search of the Somogyi effect. Lancet 1:279–282
Deckert T, Lørup B (1976) Regulation of brittle diabetics by a pre-planned insulin infusion programme. Diabetologia 12: 573–579
Clarke WR, Haymond MW, Santiago JV (1980) Overnight basal insulin requirements in fasting insulin-dependent diabetics. Diabetes 29:78–80
Peterson CM, Forhan SE, Jones RI (1980) Self-management: An approach to patients with insulin-dependent diabetes mellitus. Diabetes Care 1:82–87
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ward, G.M., Simpson, R.W., Ward, E.A. et al. Comparison of two twice-daily insulin regimens: Ultralente/soluble and soluble/isophane. Diabetologia 21, 383–386 (1981). https://doi.org/10.1007/BF00252686
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00252686